IntroductionIntuitive Surgical, Inc. (NASDAQ: ISRG) is the company most closely associated with the rise of robotic-assisted surgery. Its flagship da Vinci Surgical System has become the industry bencIntroductionIntuitive Surgical, Inc. (NASDAQ: ISRG) is the company most closely associated with the rise of robotic-assisted surgery. Its flagship da Vinci Surgical System has become the industry benc

Intuitive Surgical Stock Analysis 2026: Technical Chart Review, Fundamentals, and Price Target Forecast

#行业观察

2026/07/21 09:37

Introduction

Intuitive Surgical, Inc. (NASDAQ: ISRG) is the company most closely associated with the rise of robotic-assisted surgery. Its flagship da Vinci Surgical System has become the industry benchmark for minimally invasive procedures, and the company's newer Ion endoluminal platform has expanded its reach into lung biopsy and diagnostics. For investors researching ISRG stock analysis, Intuitive Surgical stock forecast, or robotic surgery stocks to buy, this article offers a complete, up-to-date breakdown of the company's technical chart patterns, fundamentals, growth drivers, and risks.

This analysis follows Intuitive Surgical's second-quarter 2026 earnings report, released July 16, 2026, which triggered one of the stock's sharpest single-day declines in years. We break down what happened, how the ISRG stock price today compares with Wall Street's price targets, and what the calculated ISRG technical analysis indicators show. For broader context, see Nasdaq's official ISRG listing page and Intuitive Surgical Investor Relations.

Key Highlights

Current Price: ISRG closed at $350.06 on July 21, 2026, still down ~13% from pre-earnings levels after the stock's 14.15% single-session drop on July 17 following Q2 earnings.
Q2 2026 Revenue: $2.89 billion, up 19% year-over-year, beating consensus estimates.
Procedure Growth: Worldwide procedures rose 16%; da Vinci procedures grew 15%; Ion procedures surged 36%.
Guidance: Full-year 2026 da Vinci procedure growth reaffirmed at 13.5%–15.5%, disappointing investors who wanted an upward revision.
Valuation: Trailing P/E of ~39.6x and forward P/E of ~30.8x, still a premium versus the broader medical device sector.
Analyst Sentiment: Consensus rating remains "Buy" with an average 12-month price target of $504.15, implying roughly 46% upside from current levels.
Market Cap: $122.3 billion, down roughly 43% from its 52-week high near $604.
Technical Picture: Stock has broken below key short-term moving averages and is trading near its 52-week low of $344.55.

1. Company Overview: What Does Intuitive Surgical Do?

Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical designs, manufactures, and markets robotic-assisted surgical systems that help surgeons perform minimally invasive procedures. The company's core product, the da Vinci Surgical System, combines a surgeon console, patient-side robotic arms, and 3D high-definition vision to improve precision in operations ranging from urology and gynecology to general and thoracic surgery.

Intuitive has also diversified into Ion, a robotic-assisted bronchoscopy platform for minimally invasive lung biopsies — an area of accelerating growth, with procedure volumes up 36% year-over-year in Q2 2026. The business model is largely recurring: roughly 85% of revenue comes from instruments, accessories, and service contracts tied to a growing installed base of nearly 13,000 da Vinci and Ion systems worldwide — a durable, razor-and-blade model. The company trades on the Nasdaq-100, S&P 100, and S&P 500, and is widely viewed as the bellwether for the robotic surgery and medtech industry. See the official Intuitive Surgical company profile for more.

2. Q2 2026 Earnings Breakdown: Why ISRG Stock Crashed

On July 16, 2026, Intuitive Surgical reported Q2 results that beat Wall Street estimates — yet the stock fell sharply the next session. Understanding that disconnect is central to any current Intuitive Surgical technical analysis.

2.1 The Headline Numbers

Metric	Q2 2026	Q2 2025	Change
Total Revenue	$2.89B	$2.44B	+19%
GAAP Net Income	$818M	—	—
GAAP Diluted EPS	$2.29	$1.81	+26.5%
Non-GAAP Net Income	$1.00B	$0.80B	+25%
Non-GAAP Diluted EPS	$2.80	$2.19	+27.9%
Worldwide Procedures	+16% YoY	—	—
da Vinci System Placements	468 units	395 units	+18.5%

2.2 Why the Stock Fell Despite the Beat

The sell-off was driven less by Q2 results and more by what management did not say about the rest of 2026. Investors wanted an upward revision to full-year procedure growth guidance; instead, management reaffirmed the existing 13.5%–15.5% range, closer to the midpoint. Compounding factors:

U.S. growth moderation: Domestic growth slowed versus prior quarters, even as international da Vinci procedures grew a healthier 20%.
Policy uncertainty: Management flagged potential ACA premium subsidy changes affecting U.S. patient behavior, reviving the medtech demand debate.
China and Japan softness: China tender volumes and prior Japan capital equipment constraints were cited as ongoing headwinds.
GLP-1 drug impact: Weight-loss medications may be modestly reducing demand for some bariatric and related procedures.
Class II recall: A previously disclosed recall added caution to the narrative alongside the softer guidance commentary.

For a full breakdown of the earnings call, see the original coverage from Reuters on Intuitive Surgical's Q2 2026 results and the related report on renewed medtech demand concerns.

3. ISRG Technical Analysis: 1-Year Trend, Candlestick Chart, and Key Statistics

3.0 One-Year Price Trend and Key Statistics

Zooming out to a full 12-month view shows the broader context behind the July 2026 sell-off: ISRG spent most of late 2025 in a strong uptrend, reaching a 52-week high near $603.88 in December 2025 on the back of a sharp post-earnings gap-up in October 2025, before entering a sustained downtrend through the first half of 2026 that culminated in the Q2 2026 earnings crash.

Figure 1: ISRG 1-year price chart (1Y view), showing the run-up to the December 2025 high near $604, the subsequent downtrend, and the July 2026 post-earnings drop toward the $344–351 zone. Source: TradingView (NASDAQ: ISRG).

Metric	Value	Metric	Value
Current Price	$350.06	Volume (Jul 21)	5.16M
Market Cap	$122.33B	Day's Range	$348.05 – $353.87
52-Week Low	$344.55	EPS (TTM)	$8.72
52-Week High	$603.88	P/E Ratio (TTM)	40.15x
Forward P/E	31.23x	Beta	1.46

Figures above reflect the July 17, 2026 close, sourced from StockAnalysis.com's ISRG overview page, which aggregates real-time CBOE pricing with S&P Global fundamentals. Other providers may show slightly different P/E or market-cap figures due to timing differences in share-count updates — a normal, minor variance across data vendors.

3.1 Recent Price Action: Candlestick Chart with Moving Averages and RSI

Zooming into the 50 trading sessions leading up to and following the Q2 2026 earnings report, this section applies standard technical indicators — simple moving averages (SMA), the Relative Strength Index (RSI), and Average True Range (ATR) — calculated directly from ISRG's daily OHLC (open-high-low-close) price data. Every figure below is computed from the underlying price series rather than estimated visually from the chart.

Figure 2: ISRG oscillator and moving-average readings on the daily timeframe, including RSI, Stochastic, CCI, MACD, and 10/20-day EMA and SMA levels. Source: TradingView (NASDAQ: ISRG).

Figure 2b: TradingView daily technical summary for ISRG — 15 Sell, 8 Neutral, 3 Buy signals overall, reflecting the short-term bearish structure discussed below. Source: TradingView (NASDAQ: ISRG).

3.2 Moving Average Analysis

Indicator	Value	Signal
Last Close (Jul 21)	$350.06	—
20-Day SMA	$398.08	Price 12.1% below
20-Day EMA	$392.40	Price 10.8% below
MA Structure	20-SMA below 50-SMA	Short-term bearish crossover

ISRG closed $48.02 below its 20-day SMA and $42.34 below its 20-day EMA as of July 21 — narrower than the gap seen on the July 17 crash day, but still a wide deviation historically. The averages remain in a short-term bearish structure, and a deviation this wide is statistically stretched — a condition that has historically preceded either a relief bounce toward the moving averages or a consolidation phase, rather than continued selling at the same pace.

3.3 Relative Strength Index (RSI)

The 14-day RSI touched 30.16 on July 17, the crash session, down sharply from 46.20 the prior session, and has since ticked up to roughly 32.9 as of July 21. A reading at or below 30 is conventionally read as oversold, and the stock remains just above that threshold days later, indicating the pace of the decline has outpaced typical short-term selling momentum without yet fully resolving. This is not a standalone reversal signal, but RSI readings this low on a liquid large-cap have historically coincided with at least short-term stabilization in prior corrections, though outcomes still depend on how the underlying catalyst resolves.

3.4 Volatility: Average True Range (ATR)

The 14-day ATR — a volatility measure that accounts for price gaps — peaked at $17.20 on the July 17 crash day, equal to roughly 5% of the share price at the time. This was well above ISRG's typical 2–3% ATR. Volatility has since begun to compress as the stock stabilized in the $348–$354 range through July 21, but traders should still expect a wider range than pre-earnings levels until the ATR normalizes fully.

3.5 Volume and Support Analysis

Volume confirmation: July 17 volume of 11.53 million shares was 3.93x the trailing 20-day average of 2.94 million shares — a statistically significant spike confirming institutional participation rather than thin, low-conviction selling.
Key support: The stock touched its 52-week low of $344.55 intraday on July 17 and has since held modestly above it, closing at $350.06 on July 21. This level remains the first technical support to watch — a decisive close back below it would be a more concerning signal than the initial earnings-day undershoot.
Gap structure: The July 17 session opened at $365.03, below the prior close of $402.33, leaving an unfilled gap between roughly $367 and $402 that stands as near-term resistance unless trading volume returns to fill it.

Traders who want to track these indicators live can use the interactive ISRG technical chart on StockAnalysis.com or the TradingView ISRG chart for continuously updated SMA, RSI, and MACD overlays.

4. Valuation and Key Financial Metrics

Understanding whether ISRG stock is overvalued or undervalued requires looking beyond the daily price move to core valuation multiples and balance sheet strength.

Metric	Value
Stock Price (Jul 21, 2026 close)	$350.06
Market Capitalization	$123.96B
Revenue (TTM)	$11.03B (+20.7% YoY)
Net Income (TTM)	$3.14B (+20.4% YoY)
EPS (TTM)	$8.72
Trailing P/E Ratio	40.15x
Forward P/E Ratio	31.23x
52-Week Range	$344.55 – $603.88
Beta	1.46
Dividend	None
Cash & Investments	$8.63B
Non-GAAP Gross Margin Guidance (FY26)	68.0%–69.0%

Even after the pullback, ISRG trades at a premium valuation versus the broader medical device industry, reflecting its dominant market position, recurring-revenue mix, and history of double-digit growth. A forward P/E near 30.8x still implies the market expects strong forward earnings growth, but leaves less room for error — a key reason a reaffirmed (rather than raised) guidance range triggered such a strong reaction. Live multiples are available at stockanalysis.com/stocks/isrg/statistics.

5. Wall Street Analyst Ratings and Price Targets

Following the July 16 earnings release, numerous investment banks revised their price targets on ISRG. While most trimmed their targets to reflect the softer near-term outlook, the overwhelming majority maintained Buy or Outperform ratings, underscoring continued long-term confidence in the company's growth story.

Figure 3: Revised analyst price targets following Q2 2026 earnings, versus current price and consensus target.

Firm	New Target	Prior Target	Rating
Bernstein	$685	$750	Outperform
RBC Capital	$575	$600	Outperform
Stifel	$550	$670	Buy
Citi	$500	$590	Buy
Baird	$500	$525	Outperform
Wells Fargo	$487	$654	Overweight
Raymond James	$483	$577	Outperform
TD Cowen	$485	$520	Buy
BofA Securities	$470	$515	Buy
Piper Sandler	$470	$580	Overweight
BTIG	$469	$512	Buy
Leerink Partners	$454	$573	Outperform
JPMorgan	$450	$550	Overweight
Mizuho	$400	$500	Neutral

According to aggregated data from 33 covering analysts, the consensus rating remains "Buy" with an average 12-month price target of $504.15, implying approximately 46% upside from the July 17 closing price. It's worth noting the wide dispersion between the most bearish target ($400 from Mizuho) and the most bullish ($685 from Bernstein), which reflects genuine disagreement among analysts about how much the reaffirmed guidance should be discounted. For live, continuously updated analyst data, see ISRG analyst ratings on StockAnalysis.com.

6. Valuation Scenarios: What Each Price Target Implies

Rather than treating analyst price targets as arbitrary numbers, it is useful to translate each one into an implied forward price-to-earnings (P/E) multiple using consensus FY26 EPS estimates of approximately $11.21 (derived from the forward P/E of 30.80x applied to the July 17 close of $345.42, the basis most analyst models were still using as of this writing). This shows what valuation assumption the market — or a given analyst — would need to accept for that price to be justified.

Figure 4: Implied forward P/E multiples at key bear, current, and bull price levels, based on FY26 consensus EPS of $11.21.

Scenario	Price	Implied Fwd. P/E	Interpretation
Bear case (Mizuho)	$400	35.7x	Above current 30.8x — assumes modest multiple recovery only
Current price	$350.06	31.2x	Baseline — modest recovery from the July 17 post-earnings low
Street low (Leerink)	$454	40.5x	Near pre-earnings historical average multiple
Consensus target	$504.15	45.0x	Requires multiple expansion back toward 2025 levels
Bull case (Bernstein)	$685	61.1x	Requires re-rating to growth-stock premium multiples

This clarifies the real debate: nearly all 33 covering analysts agree the business will keep growing — the disagreement is over what multiple the market should pay for that growth given the reimbursement and procedure-growth uncertainty flagged on the earnings call. The consensus target of $504.15 implies roughly a 45x forward multiple, still below where ISRG traded through much of 2025. Treat this as a framework for judging analyst targets critically, not as a prediction.

7. Growth Drivers to Watch

da Vinci 5 adoption: 246 of 468 total Q2 2026 placements were da Vinci 5 units, showing strong hospital upgrade demand.
Ion platform expansion: 36% procedure growth makes Ion a meaningful second growth engine beyond core da Vinci surgery.
International expansion: 20% international da Vinci procedure growth shows continued penetration in Europe and Asia outside China.
Recurring revenue durability: About 85% of revenue is tied to instruments, accessories, and services — a predictable, high-margin base that scales with the installed base.
Extended Use Program (2027): A planned program to extend instrument usage represents a potential future margin and utilization tailwind.
Capital return: $380 million in Q2 2026 buybacks alone, part of a cumulative 30.34 million shares repurchased to date.

8. Key Risks for ISRG Investors

Valuation risk: A premium P/E leaves little room for disappointment; a guidance miss can trigger outsized downside, as seen July 17.
Reimbursement uncertainty: Changes to ACA subsidies could influence elective surgery volumes and U.S. patient behavior.
Competitive and geographic softness: Rivals in robotic surgery, capital budget pressure in Europe and Japan, and soft China tender volumes could slow system placements.
Product recalls: A disclosed Class II recall is a reminder of regulatory and product-safety risk in medical devices.
GLP-1 substitution and tariffs: Weight-loss medications may modestly reduce demand for some procedures, while FY26 guidance already assumes a ~1% gross margin tariff impact.

9. Is ISRG Stock a Buy After the Q2 2026 Pullback?

Bulls cite Intuitive's dominant position in robotic surgery, recurring revenue durability, and continued double-digit procedure growth — Bernstein and RBC held targets above $550 post-sell-off, framing the drop as an overreaction to reaffirmed, not cut, guidance. Bears counter that even at $345, ISRG still carries a premium multiple, U.S. growth is decelerating, and reimbursement policy risk remains unresolved — Mizuho's $400 target reflects this caution. Long-term investors sometimes use drawdowns like this to average into quality compounders; traders may prefer to wait for a base above the 52-week low.

Weigh both cases against your own risk tolerance and time horizon. For further independent research, see Morningstar's ISRG stock analysis and Zacks Investment Research on ISRG.

Conclusion

Intuitive Surgical remains the clear category leader in robotic-assisted surgery, backed by 19% revenue growth, expanding margins, and a fast-growing global installed base. The July 2026 sell-off stemmed primarily from unmet expectations for raised guidance — not a fundamental breakdown — as revenue, earnings, and procedures all grew at healthy double-digit rates.

For investors researching ISRG stock forecast 2026 or best robotic surgery stocks, the combination of a bullish analyst consensus, wide price-target dispersion, an oversold RSI reading, and a stock trading near its 52-week low makes ISRG one of the more closely watched healthcare technology names heading into the second half of 2026. Combine technical chart analysis with fundamental research before deciding, and monitor upcoming quarters for confirmation of the guidance range.

Frequently Asked Questions (FAQ)

Q1. Why did Intuitive Surgical stock drop after Q2 2026 earnings?

ISRG fell 14.15% because management reaffirmed, rather than raised, its full-year 2026 da Vinci procedure growth guidance of 13.5%–15.5%, despite beating Q2 revenue and EPS estimates. Investors had priced in an upward revision, and the reaffirmed range, combined with commentary on U.S. reimbursement policy uncertainty and China tender softness, triggered the sell-off.

Q2. Is ISRG stock oversold based on technical indicators?

The 14-day RSI bottomed at 30.16 on July 17, just inside conventional oversold territory below 30, and has since ticked up to roughly 32.9 as of July 21 as the stock stabilized near $350. ATR-based daily volatility remains elevated at close to 5% of price, roughly double ISRG's typical range. This suggests the decline was technically stretched and momentum has started to level off, though RSI alone does not guarantee a durable reversal.

Q3. What does the consensus price target of $504.15 actually assume?

Reaching $504.15 would require ISRG's forward P/E to expand from its current 30.8x to roughly 45x on consensus FY26 earnings estimates — a return to the valuation levels the stock held through much of 2025, rather than a change in the underlying growth trajectory.

Q4. Does Intuitive Surgical pay a dividend?

No. Intuitive Surgical does not currently pay a dividend. The company instead returns capital to shareholders through share buybacks, having repurchased 0.9 million shares for approximately $380 million in Q2 2026 alone, part of a cumulative 30.34 million shares repurchased to date.

Q5. What is the 52-week price range for ISRG, and where does it trade now?

Intuitive Surgical has traded between $344.55 and $603.88 over the past 52 weeks. The stock touched that low intraday on July 17, 2026, immediately after the Q2 earnings reaction, and has since stabilized around $350, closing at $350.06 on July 21 — within roughly $5.50 of the 52-week low, which remains the most immediate technical support level to watch.

Q6. What products does Intuitive Surgical make?

Intuitive Surgical's core products are the da Vinci Surgical System for robotic-assisted minimally invasive surgery and the Ion endoluminal system for minimally invasive lung biopsies, along with related instruments, accessories, and service offerings that together generate roughly 85% of total revenue.

Q7. How does ISRG's Q2 2026 procedure growth compare with prior guidance?

Total worldwide procedures grew 16% year-over-year in Q2 2026, with da Vinci procedures up 15% and Ion procedures up 36%. Management maintained its full-year da Vinci procedure growth guidance at 13.5%–15.5% and said results are tracking closer to the midpoint of that range.

Disclaimer

This article is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Stock prices, earnings figures, and analyst price targets referenced above reflect publicly available data as of July 17, 2026, and are subject to change without notice. Investing in individual stocks, including ISRG, carries risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial advisor before making any investment decisions.

市场机遇

Quack AI实时价格 (Q)

----

USD

Quack AI (Q) 实时价格图表

描述：币圈脉动基于 AI 技术与公开信息，第一时间呈现最热代币趋势。如果想了解更多专业解读与深度分析，请访问新手学院。

本页面分享的文章均源自公开平台，仅供参考。该内容不代表 MEXC 的立场或观点。所有版权归 MEXC 所有。如果您认为任何内容侵犯了第三方的权益，请联系 [email protected] 以便及时删除。 MEXC 不保证任何内容的准确性、完整性或及时性，且不对基于所提供信息而采取的任何行动负责。本内容不构成财务、法律或其他专业建议，亦不应被解释为 MEXC 的推荐或认可。如需专家见解和深入分析，请造访 MEXC 学院。